NO20083214L - Pyrimidinylarylurea-derivater som omdannes til FGF-inhibitorer - Google Patents
Pyrimidinylarylurea-derivater som omdannes til FGF-inhibitorerInfo
- Publication number
- NO20083214L NO20083214L NO20083214A NO20083214A NO20083214L NO 20083214 L NO20083214 L NO 20083214L NO 20083214 A NO20083214 A NO 20083214A NO 20083214 A NO20083214 A NO 20083214A NO 20083214 L NO20083214 L NO 20083214L
- Authority
- NO
- Norway
- Prior art keywords
- compounds
- pyrimidinylarylurea
- derivatives
- converted
- fgf inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Foreliggende oppfinnelse angår heteroarylarylureaforbindelser med formelen (IA) hvori radikalene og symbolene har betydningene slik det er definert heri, anvendelsen av slike forbindelser for fremstilling av proteinkinaseavhengige sykdommer; farmasøytiske preparater som innbefatter nevnte heteroarylarylureaforbindelser, fremgangsmåter for fremstilling av slike nye forbindelser og fremgangsmåter for behandling som innbefatter anvendelsen av slike heteroarylarylureaforbindelser.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75271105P | 2005-12-21 | 2005-12-21 | |
PCT/EP2006/070046 WO2007071752A2 (en) | 2005-12-21 | 2006-12-20 | Pyrimidinyl aryl urea derivatives being fgf inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20083214L true NO20083214L (no) | 2008-09-01 |
Family
ID=37946774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20083214A NO20083214L (no) | 2005-12-21 | 2008-07-18 | Pyrimidinylarylurea-derivater som omdannes til FGF-inhibitorer |
Country Status (22)
Country | Link |
---|---|
US (2) | US8293746B2 (no) |
EP (1) | EP1976847B1 (no) |
JP (1) | JP5153645B2 (no) |
KR (1) | KR101406956B1 (no) |
CN (1) | CN101336237B (no) |
AU (1) | AU2006326989B2 (no) |
BR (1) | BRPI0620408B8 (no) |
CA (1) | CA2634047C (no) |
CR (1) | CR10072A (no) |
EA (1) | EA016438B1 (no) |
EC (1) | ECSP088561A (no) |
GE (1) | GEP20105074B (no) |
HN (1) | HN2008000949A (no) |
IL (1) | IL192093A0 (no) |
MA (1) | MA30063B1 (no) |
ME (2) | ME00011A (no) |
NO (1) | NO20083214L (no) |
SM (1) | SMP200800041B (no) |
SV (1) | SV2008002967A (no) |
TN (1) | TNSN08276A1 (no) |
WO (1) | WO2007071752A2 (no) |
ZA (1) | ZA200805092B (no) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0512324D0 (en) * | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
WO2007071752A2 (en) * | 2005-12-21 | 2007-06-28 | Novartis Ag | Pyrimidinyl aryl urea derivatives being fgf inhibitors |
JP2013503193A (ja) * | 2009-08-28 | 2013-01-31 | ジェネンテック, インコーポレイテッド | Raf阻害剤化合物およびその使用方法 |
ES2524548T3 (es) * | 2009-10-30 | 2014-12-10 | Novartis Ag | N-óxido de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperacin-1-il)-fenilamino]-pirimidin-4-il}-1-metil-urea |
AR079257A1 (es) * | 2009-12-07 | 2012-01-04 | Novartis Ag | Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
JP2013514986A (ja) * | 2009-12-18 | 2013-05-02 | ノバルティス アーゲー | 血液癌の処置方法 |
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
EP2821402B1 (en) | 2012-02-28 | 2019-08-21 | Astellas Pharma Inc. | Nitrogen-containing aromatic heterocyclic compound |
GB201204384D0 (en) | 2012-03-13 | 2012-04-25 | Univ Dundee | Anti-flammatory agents |
PT3495367T (pt) | 2012-06-13 | 2020-11-12 | Incyte Holdings Corp | Compostos tricíclicos substituídos como inibidores de fgfr |
US20150203589A1 (en) | 2012-07-24 | 2015-07-23 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
AR094812A1 (es) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
MX2015002959A (es) * | 2013-03-10 | 2015-06-05 | Univ Nagoya Nat Univ Corp | Agente terapeutico para padecimiento sistemico oseo y uso del mismo. |
JP2016515508A (ja) | 2013-03-15 | 2016-05-30 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | 融合タンパク質及びその方法 |
TWI647220B (zh) | 2013-03-15 | 2019-01-11 | 美商西建卡爾有限責任公司 | 雜芳基化合物及其用途 |
NZ711376A (en) | 2013-03-15 | 2020-01-31 | Sanofi Sa | Heteroaryl compounds and uses thereof |
AU2014228746B2 (en) | 2013-03-15 | 2018-08-30 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
EP2789619A1 (en) | 2013-04-12 | 2014-10-15 | Kemotech S.r.l. | Pharmaceutical compounds wiht angiogenesis inbhibitory activity |
TWI715901B (zh) | 2013-04-19 | 2021-01-11 | 美商英塞特控股公司 | 作為fgfr抑制劑之雙環雜環 |
CA2917667A1 (en) | 2013-07-09 | 2015-01-15 | Dana-Farber Cancer Institute, Inc. | Kinase inhibitors for the treatment of disease |
AU2014337291B9 (en) * | 2013-10-18 | 2020-05-07 | Eisai R&D Management Co., Ltd. | Pyrimidine FGFR4 inhibitors |
ES2682493T3 (es) | 2013-10-25 | 2018-09-20 | Novartis Ag | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de FGFR4 |
EP3079667B1 (en) | 2013-12-13 | 2019-06-26 | Novartis AG | Pharmaceutical dosage forms |
EP3171874B1 (en) | 2014-07-21 | 2020-11-18 | Dana-Farber Cancer Institute, Inc. | Imidazolyl kinase inhibitors and uses thereof |
DK3172213T3 (da) | 2014-07-21 | 2021-12-13 | Dana Farber Cancer Inst Inc | Makrocykliske kinasehæmmere og anvendelser deraf |
EP3536323A1 (en) * | 2014-08-08 | 2019-09-11 | Dana Farber Cancer Institute, Inc. | Uses of salt-inducible kinase (sik) inhibitors |
MX369646B (es) | 2014-08-18 | 2019-11-15 | Eisai R&D Man Co Ltd | Sal de derivado de piridina monociclico y su cristal. |
US20180185341A1 (en) * | 2014-10-03 | 2018-07-05 | Novartis Ag | Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
EP3237452A4 (en) | 2014-12-23 | 2018-12-05 | The Trustees of Columbia University in the City of New York | Fusion proteins and methods thereof |
CN113004278B (zh) | 2015-02-20 | 2023-07-21 | 因赛特控股公司 | 作为fgfr抑制剂的双环杂环 |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
US9802917B2 (en) | 2015-03-25 | 2017-10-31 | Novartis Ag | Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide |
MX2017013248A (es) | 2015-04-14 | 2018-07-06 | Eisai R&D Man Co Ltd | Compuesto del inhibidor fgfr4 cristalino y usos del mismo. |
CN104803925B (zh) * | 2015-04-16 | 2018-01-12 | 温州医科大学 | 一类以fgfr为靶点的2,4,5‑三取代嘧啶类化合物及其制备方法和用途 |
US10624897B2 (en) | 2015-07-20 | 2020-04-21 | Taipei Medical University | Chlorobenzene substituted azaaryl compounds |
WO2017118438A1 (zh) * | 2016-01-08 | 2017-07-13 | 杭州英创医药科技有限公司 | 作为fgfr抑制剂的杂环化合物 |
EP3454898B1 (en) | 2016-05-10 | 2021-11-10 | Eisai R&D Management Co., Ltd. | Drug combinations for reducing cell viability and/or cell proliferation |
CN110225914A (zh) | 2016-07-05 | 2019-09-10 | 布罗德研究所股份有限公司 | 双环脲激酶抑制剂及其用途 |
WO2018053373A1 (en) | 2016-09-16 | 2018-03-22 | The General Hospital Corporation | Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis |
DK3555070T3 (da) * | 2016-12-19 | 2023-09-18 | Epizyme Inc | Aminsubstituerede, heterocykliske forbindelser som ehmt2-hæmmere og fremgangsmåder til anvendelse deraf |
JP7296318B2 (ja) | 2017-02-28 | 2023-06-22 | ザ ジェネラル ホスピタル コーポレイション | Sikインヒビターとしてのピリミドピリミジノンの使用 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
WO2019189241A1 (ja) | 2018-03-28 | 2019-10-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 肝細胞癌治療剤 |
WO2019213544A2 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
CR20200591A (es) | 2018-05-04 | 2021-03-31 | Incyte Corp | Sales de un inhibidor de fgfr |
CN109053593B (zh) * | 2018-08-07 | 2020-12-04 | 温州医科大学 | 1-(2,6-氯苯基)-3-(取代嘧啶-4-基)脲类化合物及其制备和应用 |
CN109053594B (zh) * | 2018-08-07 | 2020-12-18 | 温州医科大学 | 1-(3,5-二甲氧基苯基)-3-(取代嘧啶-4-基)脲类化合物及其制备和应用 |
CN109053592B (zh) * | 2018-08-07 | 2020-12-04 | 温州医科大学 | 1-(2,5-二甲氧基苯基)-3-(取代嘧啶-4-基)脲类化合物及其制备和应用 |
WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
CN110283130B (zh) * | 2019-07-05 | 2023-12-19 | 温州医科大学 | 一种1-(2,5-二甲氧基苯基)-3-取代脲类结肠癌抑制剂及其制备和应用 |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
TW202128685A (zh) | 2019-10-14 | 2021-08-01 | 美商英塞特公司 | 作為fgfr抑制劑之雙環雜環 |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
CA3162010A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3759921A (en) * | 1969-10-16 | 1973-09-18 | Lilly Co Eli | Method of suppressing immuneresponse with 1 substituted-3-(2 pyrimidyl)ureas |
US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
MXPA02003436A (es) * | 1999-10-07 | 2002-08-20 | Amgen Inc | Inhibidores de triazina cinasa. |
ES2282299T3 (es) * | 2000-10-20 | 2007-10-16 | EISAI R&D MANAGEMENT CO., LTD. | Compuestos aromaticos con anillos de nitrogeno como agentes anticancerigenos. |
UA76977C2 (en) | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
ITMI20010528A1 (it) | 2001-03-13 | 2002-09-13 | Istituto Biochimico Pavese Pha | Complessi di resveratrolo con fosfolipidi loro preparazione e composizioni farmaceutiche e cosmetiche |
US20020156257A1 (en) | 2001-03-29 | 2002-10-24 | Chunhua Yan | Isolated human Ras-like proteins, nucleic acid molecules encoding these human Ras-like proteins, and uses thereof |
GB0201508D0 (en) * | 2002-01-23 | 2002-03-13 | Novartis Ag | Organic compounds |
TW200406374A (en) | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
WO2003101444A1 (en) | 2002-05-29 | 2003-12-11 | Millennium Pharmaceuticals, Inc. | Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer |
US20040034038A1 (en) * | 2002-08-13 | 2004-02-19 | Goaquan Li | Urea kinase inhibitors |
AU2003299750A1 (en) | 2002-12-20 | 2004-07-22 | Irm Llc | Differential tumor cytotoxocity compounds and compositions |
WO2005030735A1 (en) | 2003-09-25 | 2005-04-07 | Ranbaxy Laboratories Limited | Triazines derivatives as cell adhesion inhibitors |
TW200529849A (en) | 2003-11-28 | 2005-09-16 | Novartis Ag | Diaryl urea derivatives in the treatment of protein kinase dependent diseases |
US20070293484A1 (en) | 2004-05-20 | 2007-12-20 | Sugen, Inc. | Thiophene Heteroaryl Amines |
UY28931A1 (es) | 2004-06-03 | 2005-12-30 | Bayer Pharmaceuticals Corp | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis |
GB0512324D0 (en) * | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
WO2006038112A1 (en) | 2004-10-01 | 2006-04-13 | Warner-Lambert Company Llc | Use of kinase inhibitors to promote neochondrogenesis |
CA2586870A1 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Il-12 modulatory compounds |
EP1928843A1 (en) * | 2005-08-22 | 2008-06-11 | Amgen, Inc | Bis-aryl urea compounds for the treatment of protein kinase-mediated diseaes |
WO2007071752A2 (en) * | 2005-12-21 | 2007-06-28 | Novartis Ag | Pyrimidinyl aryl urea derivatives being fgf inhibitors |
US20090062320A1 (en) * | 2007-08-28 | 2009-03-05 | Vito Guagnano | Method of Treating Disorders Mediated by the Fibroblast Growth Factor Receptor |
-
2006
- 2006-12-20 WO PCT/EP2006/070046 patent/WO2007071752A2/en active Application Filing
- 2006-12-20 KR KR1020087017819A patent/KR101406956B1/ko active IP Right Grant
- 2006-12-20 CN CN200680051955.3A patent/CN101336237B/zh active Active
- 2006-12-20 SM SM200800041T patent/SMP200800041B/it unknown
- 2006-12-20 EA EA200801565A patent/EA016438B1/ru not_active IP Right Cessation
- 2006-12-20 JP JP2008546461A patent/JP5153645B2/ja active Active
- 2006-12-20 ME MEP-2008-38A patent/ME00011A/me unknown
- 2006-12-20 BR BRPI0620408A patent/BRPI0620408B8/pt active IP Right Grant
- 2006-12-20 EP EP06830765.1A patent/EP1976847B1/en active Active
- 2006-12-20 CA CA2634047A patent/CA2634047C/en active Active
- 2006-12-20 GE GEAP200610763A patent/GEP20105074B/en unknown
- 2006-12-20 US US12/158,873 patent/US8293746B2/en active Active
- 2006-12-20 AU AU2006326989A patent/AU2006326989B2/en active Active
- 2006-12-20 ME MEP-38/08A patent/MEP3808A/xx unknown
-
2008
- 2008-06-11 ZA ZA200805092A patent/ZA200805092B/xx unknown
- 2008-06-12 IL IL192093A patent/IL192093A0/en unknown
- 2008-06-13 CR CR10072A patent/CR10072A/es not_active Application Discontinuation
- 2008-06-18 MA MA31047A patent/MA30063B1/fr unknown
- 2008-06-19 EC EC2008008561A patent/ECSP088561A/es unknown
- 2008-06-20 HN HN2008000949A patent/HN2008000949A/es unknown
- 2008-06-20 SV SV2008002967A patent/SV2008002967A/es not_active Application Discontinuation
- 2008-06-20 TN TNP2008000276A patent/TNSN08276A1/en unknown
- 2008-07-18 NO NO20083214A patent/NO20083214L/no not_active Application Discontinuation
-
2012
- 2012-09-21 US US13/624,320 patent/US8759517B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20083214L (no) | Pyrimidinylarylurea-derivater som omdannes til FGF-inhibitorer | |
NO20080981L (no) | Nitrocatechol-derivater som COMT-inhibitorer | |
EA201190158A1 (ru) | Производные бензофуранила для применения в качестве ингибиторов глюкокиназы | |
TN2009000128A1 (en) | Dihydropyridine derivatives useful as protein kinase inhibitors | |
EA201100311A1 (ru) | Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы | |
NO20090202L (no) | Prolylhydroksylaseinhibitorer | |
NO20071504L (no) | Pyrimidinderivanter. | |
NO20090783L (no) | Pyrimidonforbindelser som inhibitorer av GSK-3 | |
NO20090628L (no) | Pyridizinon derivativater | |
IN2014KN00929A (no) | ||
NO20071246L (no) | Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer. | |
NO20071245L (no) | Kinazolinonderivater og deres anvendelse som b-RAF-inhibitorer. | |
NO20081893L (no) | 4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft | |
NO20084202L (no) | 4-anilinoquinolin-3-carboksamider som CSF-1R kinase inhibitorer | |
NO20073859L (no) | Pyrrolopyrazoler, potente kinaseinhibitorer | |
NO20081454L (no) | Met-kinaseinhibitorer | |
NO20090295L (no) | Substituerte heteroarylderivater | |
NO20081729L (no) | Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer | |
NO20074634L (no) | Substituerte heterocykler og deres anvendelse som CHK1-, PDK1- og PAK-inhibitorer | |
NO20091683L (no) | Kjemiske forbindelser | |
UA107951C2 (en) | Imidazopyridine derivatives as inhibitors of jak | |
NO20082124L (no) | Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom | |
NO20063449L (no) | Substituerte heterocykler og deres anvendelse | |
UA107188C2 (uk) | Карбоксамідні похідні хіназолінів або хінолінів та фармацевтична композиція на їх основі | |
NO20084712L (no) | Nye farmasoytiske forbindelser |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |